40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Paralel Advisors LLC

Paralel Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 40,919 shares of the biotechnology company’s stock, valued at approximately $2,341,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its holdings in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC increased its stake in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 183 shares during the period. Caerus Investment Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 2.8% during the fourth quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock valued at $608,000 after buying an additional 278 shares during the period. Chicago Partners Investment Group LLC raised its holdings in shares of BioMarin Pharmaceutical by 2.4% in the first quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 290 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 295 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Stock Down 2.4%

Shares of BioMarin Pharmaceutical stock opened at $67.68 on Friday. The firm’s 50 day moving average price is $60.45 and its 200-day moving average price is $57.82. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98. The company has a market cap of $13.10 billion, a P/E ratio of 182.92, a PEG ratio of 0.50 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

BMRN has been the topic of several recent research reports. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group boosted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a report on Monday, August 10th. The Goldman Sachs Group assumed coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price target for the company. UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Finally, BMO Capital Markets started coverage on shares of BioMarin Pharmaceutical in a report on Wednesday. They set an “outperform” rating and a $98.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.83.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BMO upgrades BioMarin to “strong buy.” The upgrade follows BMO’s recent initiation of coverage with an “outperform” rating and a $98 price target, implying substantial upside from the current trading level. BMO upgrades BioMarin to strong buy
• Positive Sentiment: Alesta acquisition expands BioMarin’s rare-disease pipeline. BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal adds ALE1, an oral treatment candidate for hypophosphatasia, a rare genetic bone disorder, and could strengthen the company’s long-term growth prospects if development and regulatory milestones are achieved. BioMarin Alesta acquisition
• Positive Sentiment: Recent operating results were stronger than expected. BioMarin’s latest reported quarter exceeded consensus earnings and revenue estimates, with revenue increasing 20% year over year. Articles from Barclays and Piper Sandler also point to potential share-price appreciation. BioMarin Q2 results benchmarking
• Neutral Sentiment: The Alesta opportunity remains early stage. ALE1 is still in clinical development, meaning the potential commercial benefit is several years away and depends on successful trials, approvals and milestone execution. The transaction therefore adds strategic potential but also development risk. BioMarin to acquire Alesta
• Negative Sentiment: Analyst opinion is not unanimous. HC Wainwright issued a pessimistic forecast, while another analyst reduced the price target to $59 despite viewing the Alesta deal favorably. This valuation disagreement may limit near-term upside and contribute to selling pressure. BioMarin analyst price target cut

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.